The Verge quoted GHTC Director Jamie Bay Nishi in an article on developing drugs and products amidst an outbreak.
Statement from Jamie Bay Nishi, Director, Global Health Technologies Coalition, on the US Food and Drug Administration’s approval of pretomanid, a new drug developed by the nonprofit TB Alliance.
The Los Angeles Times quoted GHTC Director Jamie Bay Nishi in an article on the FDA approval of a new drug to treat highly resistant tuberculosis.
CIDRAP quoted GHTC Director Jamie Bay Nishi in an article on the FDA approval of a new drug to treat highly resistant tuberculosis.
The European Sting reposted a commentary piece co-authored by GHTC Director Jamie Bay Nishi, first published in World Economic Forum's Agenda, on the importance of public-private partnerships and innovation to achieving universal health coverage (UHC).
Statement from Jamie Bay Nishi, Director, Global Health Technologies Coalition, on the US Food and Drug Administration’s approval of pretomanid, a new drug developed by the nonprofit TB Alliance.
This legislation is an important step forward in strengthening our nation’s preparedness against global disease threats. We applaud the Administration and Congress for recognizing that protecting our nation’s health requires deploying BARDA’s unique capabilities to combat all hazards—not only chemical, biological, radiological and nuclear threats, but naturally occurring health threats as well.
GHTC has opened nominations for its 2019 Innovating for Impact Awards. Now in its third year, this initiative celebrates the partnerships and policymakers driving global health innovation. The nomination deadline is July 31, 2019.
The passage of PAHPAI is an important action by Congress to strengthen our nation’s preparedness against global disease threats. We applaud Congress for recognizing that protecting our nation’s health requires deploying BARDA’s unique capabilities to combat all hazards—not only chemical, biological, radiologic and nuclear threats, but naturally occurring health threats as well.
Next week’s World Health Assembly will be setting priorities that have enormous life-altering implications for billions of people around the world. The Global Health Technologies Coalition (GHTC) is calling on World Health Organization (WHO) member states to increase investments in research and development (R&D), as new tools and technologies are essential for meeting urgent challenges, from achieving universal health coverage (UHC) to fighting antimicrobial resistance (AMR), including drug-resistant tuberculosis (DR-TB), and emerging threats like Ebola.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.
The Verge quoted GHTC Director Jamie Bay Nishi in an article on developing drugs and products amidst an outbreak.
The Los Angeles Times quoted GHTC Director Jamie Bay Nishi in an article on the FDA approval of a new drug to treat highly resistant tuberculosis.
CIDRAP quoted GHTC Director Jamie Bay Nishi in an article on the FDA approval of a new drug to treat highly resistant tuberculosis.
The European Sting reposted a commentary piece co-authored by GHTC Director Jamie Bay Nishi, first published in World Economic Forum's Agenda, on the importance of public-private partnerships and innovation to achieving universal health coverage (UHC).
Healio Infectious Disease News quoted GHTC Director Jamie Bay Nishi in an article on the signing into law of the Pandemic and All-Hazards Preparedness and Advancing Innovation Act.
GHTC joined other advocates in endorsing the Comprehensive TB Elimination Act of 2019, which would enhance tuberculosis (TB) R&D at the National Institutes of Health and facilitate coordination of late stage R&D of new TB diagnostic, treatment, and prevention tools with the Biomedical Advanced Research and Development Authority.
A statement by GHTC and partners calling on the World Health Organization and member states to close the US$1.3 billion gap in annual TB R&D funding was made at the 72nd World Health Assembly. The statement urges countries to invest in the development of new medicines and technologies to treat multidrug-resistant TB and to facilitate rapid and equitable access to these interventions.
A statement by GHTC and partners encouraging innovative technologies and approaches to accelerate universal influenza vaccine research and development was made at the 72nd World Health Assembly. This statement recognizes pandemic influenza as a looming global health threat and encourages the World Health Organization and member states to increase investment and collaborative action to accelerate development of a universal flu vaccine.
A statement by GHTC and partners noting that innovation and R&D must be at the heart of any agenda to tackle AMR was delivered at the 72nd World Health Assembly. The statement applauds World Health Organization member states for recognizing the need for new antimicrobials, vaccines, and diagnostics, and urges continued progress on commitments made at the United Nations (UN) High-Level Meeting.
A statement by GHTC and partners emphasizing the importance of innovation and R&D as a central pillar of universal health coverage (UHC) was made at the 72nd World Health Assembly. The statement calls for the Political Declaration to include language to strengthen health systems down to the community level by investing in R&D to ensure quality care for all.
